Trevi Therapeutics Appoints New Chief Financial Officer
Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth.
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company, has announced that David Hastings will be stepping into the role of Chief Financial Officer starting January 6, 2026. This decision reflects Trevi's commitment to enhancing its leadership team as it advances its investigational therapy Haduvio™ aimed at treating chronic cough associated with idiopathic pulmonary fibrosis and other conditions.
David Hastings brings with him more than 25 years of experience in financial leadership within public life sciences and biopharmaceutical firms. His impressive career includes significant achievements in capital raising, commercialization, and investor relations management. Notably, he has successfully secured over $2 billion through equity and debt financing. Before joining Trevi, Hastings served as CFO at Arbutus Biopharma from June 2018 until March 2025, contributing to strategic financial management during his tenure.
Prior to his role at Arbutus, Hastings held the position of Senior Vice President and CFO at Unilife from 2015 to 2017. His career also includes a substantial period at Incyte, where he played an essential role from 2003 to 2014. At Incyte, he managed the financial intricacies of the company's transition from R&D to commercialization, particularly following the successful launch of Jakafi® (ruxolitinib). His leadership was vital in scaling the company to support a growing workforce of over 700 employees and negotiating significant licensing agreements.
Trevi Therapeutics' President and CEO, Jennifer Good, expressed her enthusiasm about Hastings joining the team, stating, "I am thrilled to welcome Dave to the leadership team as we enter an important chapter of growth at Trevi. His proven track record and experience as we transition into Phase 3 development and beyond will be critical as we continue to advance Haduvio for the treatment of chronic cough." This sentiment highlights the pivotal role Hastings will play in facilitating Trevi's strategic objectives and pushing forward its therapeutic innovations.
Hastings himself expressed excitement about his new position within Trevi. He stated, "I am happy to join Trevi as they continue to pioneer a potential treatment option for patients with chronic cough. Trevi is at an exciting stage of development with statistically significant data across target indications, limited competition, and a strong cash position. I look forward to leveraging my experience to accelerate its path to long-term value for both patients and shareholders." His remarks indicate a strong alignment with Trevi’s mission to meet the needs of patients suffering from chronic cough conditions.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is dedicated to developing innovative biopharmaceutical therapies, specifically focusing on Haduvio™ (oral nalbuphine extended-release). This therapy targets chronic cough in patients with idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. Haduvio has demonstrated a statistically significant reduction in cough frequency, a breakthrough in a field with considerable unmet needs. It works by acting on opioid receptors which are pivotal in controlling chronic coughing episodes.
Chronic cough, particularly among patients with conditions like idiopathic pulmonary fibrosis and non-IPF ILD, remains a significant challenge. It affects approximately 150,000 individuals in the U.S. with IPF, two-thirds of whom experience uncontrolled chronic cough. Furthermore, around 228,000 U.S. patients with non-IPF ILD report similar issues. The condition can drastically impair quality of life, leading to serious health complications and increased healthcare utilization.
Refractory chronic cough, defined as a persistent cough lasting more than eight weeks despite addressing underlying issues, also poses a growing concern, impacting approximately 2-3 million U.S. patients. These individuals may suffer from heightened cough reflex sensitivity that affects their daily lives both physically and psychologically. With no FDA-approved therapies currently available, the introduction of Haduvio aims to fill this gap in treatment options for chronic cough sufferers.
Trevi is naming Haduvio as the trade name for oral nalbuphine ER. It's essential to note that the safety and efficacy of this investigational therapy have not yet been evaluated by regulatory authorities.
For further details, visit Trevi's official website and engage with the company on social media platforms.
Frequently Asked Questions
What is Trevi Therapeutics known for?
Trevi Therapeutics specializes in developing novel therapies for chronic cough conditions, particularly with its investigational product Haduvio.
Who is David Hastings?
David Hastings is the newly appointed Chief Financial Officer of Trevi Therapeutics, bringing extensive experience in biotech financial management.
What challenges are chronic cough patients facing?
Chronic cough patients often experience significant health issues, with currently no FDA-approved therapies available to manage their symptoms effectively.
When does David Hastings officially start at Trevi?
David Hastings is set to begin his role as Chief Financial Officer on January 6, 2026.
How does Haduvio work?
Haduvio acts on the cough reflex arc as an opioid receptor modulator, providing relief for chronic cough by targeting both central and peripheral mechanisms involved in cough control.
